I just got back from judging elementary level science fair (this is like kids in 6th grade or something). Here are some quick notes in no particular order. Please, please do not have a 20 item list of ...

Every other year in February, the world of oceanography descends upon a conference center somewhere in the world to talk science, showcase innovations and network. It is a chance to see and be seen ...

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced a moderated digital poster presentation at ...

Charlie Smith. Poster exhibit. Case of Fetal Immature Trauma. The Southern Radiological Conference, Marriott's Grand Hotel, Resort and Spa, Point Clear, Alabama, January 25-27, 2013. Charlie Smith.

VoiceThread Recording Submission Deadline (for those accepted for Virtual and In-person Posters): Jan. 26, 2026 at 5 p.m. Upon abstract acceptance, all posters must be uploaded and recorded on ...

WALTHAM, Mass.--(BUSINESS WIRE)--Avilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today announced a scientific poster presentation highlighting ATACs ...

ASC30 is an investigational GLP-1R biased small molecule agonist and has unique and differentiated properties that enable the same small molecule for both oral tablet and subcutaneous injection ...

SAN DIEGO, Oct. 9, 2012 /PRNewswire/ -- Receptos Inc. today announced that company personnel will deliver two scientific poster presentations about RPC1063 at the Congress of the European Committee ...

Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% Compared to Placebo – – An Exploratory Analysis of CLEAR ...

LEIDEN, Netherlands--(BUSINESS WIRE)--Azafaros B.V., a clinical-stage biotechnology company focused on rare diseases and lysosomal storage disorders, today announced that advancements with its lead ...

Del-zota produced statistically significant increases in exon skipping and dystrophin levels in EXPLORE44, a Phase 1/2 study in patients with DMD44 (oral presentation) Aravindhan Veerapandiyan, MD, ...